Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma

被引:16
作者
Catalano, Martina [1 ]
Casadei-Gardini, Andrea [2 ]
Vannini, Gianmarco [1 ]
Campani, Claudia [3 ]
Marra, Fabio [3 ,4 ]
Mini, Enrico [5 ]
Roviello, Giandomenico [5 ]
机构
[1] Univ Florence, Sch Human Hlth Sci, Florence, Italy
[2] Univ Vita Salute, San Raffaele Hosp IRCCS, Dept Med Oncol, Milan, Italy
[3] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[4] Excellence Ctr Res Transfer Snd High Educ DenoTHE, Florence, Italy
[5] Univ Florence, Dept Hlth Sci, Florence, Italy
关键词
Advanced HCC; combination therapy; lenvatinib; tyrosine kinase inhibitor; FIBROBLAST-GROWTH-FACTOR; ATEZOLIZUMAB PLUS BEVACIZUMAB; TYROSINE KINASE INHIBITOR; ADVERSE EVENTS; TUMOR MICROENVIRONMENT; ANTITUMOR ACTIVITIES; T-CELLS; SORAFENIB; SURVIVAL; EFFICACY;
D O I
10.1080/17512433.2021.1958674
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction : The evolving therapeutic landscape of advanced hepatocellular carcinoma (HCC) includes the increasing implementation of target-therapy and immunotherapy. Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma. Its approval has changed the scenario of first-line therapies for advanced HCC, where just sorafenib proved clinical efficacy for over a decade. Areas covered : The current evidence on the role of lenvatinib for patients with advanced HCC is reviewed in this article. Particularly, therapeutic mechanisms and clinical efficacy of lenvatinib are summarized and the management of adverse events is discussed. In addition, future perspectives on the emerging role of combine therapy for HCC are highlighted. Expert Opinion In the first line, lenvatinib was found to be non-inferior to sorafenib for overall survival, with significantly better progression-free survival and objective response rate. Immune checkpoint inhibitors (ICIs) are now part of HCC treatment, and recently the combination of atezolizumab plus bevacizumab has become the recommended standard of care first-line therapy for selected patients. The antitumor and immunomodulatory activities that lenvatinib shows in preclinical studies, and the positive outcomes achieved using a combination of lenvatinib plus ICIs, open new perspectives for advanced HCC treatment.
引用
收藏
页码:1353 / 1365
页数:13
相关论文
共 125 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]   The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 [J].
Akinyemiju, Tomi ;
Abera, Semaw ;
Ahmed, Muktar ;
Alam, Noore ;
Alemayohu, Mulubirhan Assefa ;
Allen, Christine ;
Al-Raddadi, Rajaa ;
Alvis-Guzman, Nelson ;
Amoako, Yaw ;
Artaman, Al ;
Ayele, Tadesse Awoke ;
Barac, Aleksandra ;
Bensenor, Isabela ;
Berhane, Adugnaw ;
Bhutta, Zulfiqar ;
Castillo-Rivas, Jacqueline ;
Chitheer, Abdulaal ;
Choi, Jee-Young ;
Cowie, Benjamin ;
Dandona, Lalit ;
Dandona, Rakhi ;
Dey, Subhojit ;
Dicker, Daniel ;
Phuc, Huyen ;
Ekwueme, Donatus U. ;
Zaki, Maysaa El Sayed ;
Fischer, Florian ;
Furst, Thomas ;
Hancock, Jamie ;
Hay, Simon I. ;
Hotez, Peter ;
Jee, Sun Ha ;
Kasaeian, Amir ;
Khader, Yousef ;
Khang, Young-Ho ;
Kumar, G. Anil ;
Kutz, Michael ;
Larson, Heidi ;
Lopez, Alan ;
Lunevicius, Raimundas ;
Malekzadeh, Reza ;
McAlinden, Colm ;
Meier, Toni ;
Mendoza, Walter ;
Mokdad, Ali ;
Moradi-Lakeh, Maziar ;
Nagel, Gabriele ;
Nguyen, Quyen ;
Nguyen, Grant ;
Ogbo, Felix .
JAMA ONCOLOGY, 2017, 3 (12) :1683-1691
[3]   Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma [J].
Alsina, Angel ;
Kudo, Masatoshi ;
Vogel, Arndt ;
Cheng, Ann-Lii ;
Tak, Won Young ;
Ryoo, Baek-Yeol ;
Evans, Thomas R. Jeffry ;
Lopez Lopez, Carlos ;
Daniele, Bruno ;
Misir, Soamnauth ;
Ren, Min ;
Izumi, Namiki ;
Qin, Shukui ;
Finn, Richard S. .
LIVER CANCER, 2020, 9 (01) :93-104
[4]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[5]  
[Anonymous], SAFETY EFFICACY LENV
[6]   Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma An Analysis of 1160 Cases From a Nationwide Survey [J].
Aoki, Taku ;
Kokudo, Norihiro ;
Matsuyama, Yutaka ;
Izumi, Namiki ;
Ichida, Takafumi ;
Kudo, Masatoshi ;
Ku, Yonson ;
Sakamoto, Michiie ;
Nakashima, Osamu ;
Matsui, Osamu ;
Makuuchi, Masatoshi .
ANNALS OF SURGERY, 2014, 259 (03) :532-542
[7]   Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer [J].
Arai, Nobuhiko ;
Sasaki, Hikaru ;
Tamura, Ryota ;
Ohara, Kentarou ;
Yoshida, Kazunari .
WORLD NEUROSURGERY, 2017, 107 :1047.e9-1047.e15
[8]   RET tyrosine kinase signaling in development and cancer [J].
Arighi, E ;
Borrello, MG ;
Sariola, H .
CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (4-5) :441-467
[9]   Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination [J].
Bose, Anamika ;
Taylor, Jennifer L. ;
Alber, Sean ;
Watkins, Simon C. ;
Garcia, Jorge A. ;
Rini, Brian I. ;
Ko, Jennifer S. ;
Cohen, Peter A. ;
Finke, James H. ;
Storkus, Walter J. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (09) :2158-2170
[10]  
Brose Marcia S, 2014, Semin Oncol, V41 Suppl 2, pS1, DOI 10.1053/j.seminoncol.2014.01.001